Comment from Otsuka Pharmaceutical Development & Commercialization, Inc.

Summary: Otsuka Pharmaceutical Development & Commercialization, Inc. supports the FDA's initiative to understand the impacts of patient-focused drug development (PFDD) meetings. The company provides specific examples of how these meetings have helped identify unmet needs, inform research initiatives, and shape conceptual frameworks for diseases like PKU, schizophrenia, and IgA nephropathy.